-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Due to the lack of varieties, vague dosages and lack of specifications in the field of children's medicine, there is still a large unmet demand.
Therefore, the children's medicine market needs to be further developed
.
In 2019, the newly revised Drug Administration Law encouraged the development and innovation of children's medicines, supported the development of new varieties, dosage forms and specifications of children's medicines that meet the physiological characteristics of children, and given priority review and approval to children's medicines; March 2020 In January, the newly revised "Measures for the Administration of Drug Registration" was announced, which clearly pointed out that new varieties, dosage forms and specifications of children's drugs that meet the physiological characteristics of children can apply for the priority review and approval process
.
A series of policy support has given major pharmaceutical companies a "strengthening shot" and increased their enthusiasm for research and development
.
Up to now, the National Health and Construction Commission has released three batches of lists of children's drugs that encourage R&D and declaration in May 2016, May 2017 and July 2019, respectively, and a total of 106 varieties have been included in the list, most of which have been marketed abroad but lacked in China.
The release of these lists has pointed out the direction for the research and development of pediatric drugs in China
.
In recent years, major pharmaceutical companies are also willing to accelerate their deployment in the field of children's medicine
.
For example, it was reported on January 1 that the company will focus on the fields of children's pharmaceuticals and health, strengthen technology research and development, strengthen brand building, continue to improve the company's core competitiveness, and strive to achieve the company's healthy and stable development
.
However, in terms of mergers and acquisitions of children's drugs, the company recently stated that there is no clear merger and acquisition plan at present
.
On December 28, 2021, Kangzhi Pharmaceutical stated that in the 2021 provincial-level "specialized, special and new" list of small and medium-sized enterprises recently announced by the Hainan Provincial Department of Industry and Information Technology, Kangzhi Pharmaceutical was successfully shortlisted, demonstrating the company's presence in the industry.
Strength and heritage in the field of children's health
.
In the future, the company plans to continue to specialize in children's health, and strengthen the research and development of Chinese patent medicines for children and adults
.
For another example, in the field of drugs that are clinically scarce for children with rare diseases in China, on December 17, 2021, Sunflower Pharmaceuticals and Dr.
Ruidi announced that they would "join hands" and will introduce two drugs for children with rare diseases that have been approved for marketing overseas.
Sunflower Pharmaceuticals is responsible for the import and local sales, marketing and distribution of the two drugs in China
.
It is reported that in addition to the introduction of drugs, Sunflower Pharmaceutical also plans to promote academic sharing of common clinical diagnosis and treatment errors, improve the clinical diagnosis rate of rare diseases, and help patients find and treat early
.
The research and development of new drugs is characterized by high investment, long payback period and high risk.
From the perspective of the industry, in the past, pharmaceutical companies were not very willing to develop children's drugs, mainly because of the long cycle, high cost, low profit, and lack of corporate research and development motivation.
If there is no confidence to invest in R&D, as multiple departments jointly formulate policies, guide R&D to "open source and reduce expenditure", and open up green channels for review, etc.
, certain support from policy and economic levels has been given, which has increased the confidence of enterprises in R&D and production of children's medicines
.
However, the industry also pointed out that to mobilize the enthusiasm of enterprises for R&D and production, it is also necessary to ensure that the relevant drugs remain within a reasonable profit range in order to improve the level of clinical children's drug use
.
For example, it is possible to explore a suitable procurement method specifically for the field of children's medicine, giving enterprises more enthusiasm for production
.
In general, the road to research and development of medicines for children is long, and the joint efforts of all links and relevant departments will be required in the future
.
Therefore, the children's medicine market needs to be further developed
.
In 2019, the newly revised Drug Administration Law encouraged the development and innovation of children's medicines, supported the development of new varieties, dosage forms and specifications of children's medicines that meet the physiological characteristics of children, and given priority review and approval to children's medicines; March 2020 In January, the newly revised "Measures for the Administration of Drug Registration" was announced, which clearly pointed out that new varieties, dosage forms and specifications of children's drugs that meet the physiological characteristics of children can apply for the priority review and approval process
.
A series of policy support has given major pharmaceutical companies a "strengthening shot" and increased their enthusiasm for research and development
.
Up to now, the National Health and Construction Commission has released three batches of lists of children's drugs that encourage R&D and declaration in May 2016, May 2017 and July 2019, respectively, and a total of 106 varieties have been included in the list, most of which have been marketed abroad but lacked in China.
The release of these lists has pointed out the direction for the research and development of pediatric drugs in China
.
In recent years, major pharmaceutical companies are also willing to accelerate their deployment in the field of children's medicine
.
For example, it was reported on January 1 that the company will focus on the fields of children's pharmaceuticals and health, strengthen technology research and development, strengthen brand building, continue to improve the company's core competitiveness, and strive to achieve the company's healthy and stable development
.
However, in terms of mergers and acquisitions of children's drugs, the company recently stated that there is no clear merger and acquisition plan at present
.
On December 28, 2021, Kangzhi Pharmaceutical stated that in the 2021 provincial-level "specialized, special and new" list of small and medium-sized enterprises recently announced by the Hainan Provincial Department of Industry and Information Technology, Kangzhi Pharmaceutical was successfully shortlisted, demonstrating the company's presence in the industry.
Strength and heritage in the field of children's health
.
In the future, the company plans to continue to specialize in children's health, and strengthen the research and development of Chinese patent medicines for children and adults
.
For another example, in the field of drugs that are clinically scarce for children with rare diseases in China, on December 17, 2021, Sunflower Pharmaceuticals and Dr.
Ruidi announced that they would "join hands" and will introduce two drugs for children with rare diseases that have been approved for marketing overseas.
Sunflower Pharmaceuticals is responsible for the import and local sales, marketing and distribution of the two drugs in China
.
It is reported that in addition to the introduction of drugs, Sunflower Pharmaceutical also plans to promote academic sharing of common clinical diagnosis and treatment errors, improve the clinical diagnosis rate of rare diseases, and help patients find and treat early
.
The research and development of new drugs is characterized by high investment, long payback period and high risk.
From the perspective of the industry, in the past, pharmaceutical companies were not very willing to develop children's drugs, mainly because of the long cycle, high cost, low profit, and lack of corporate research and development motivation.
If there is no confidence to invest in R&D, as multiple departments jointly formulate policies, guide R&D to "open source and reduce expenditure", and open up green channels for review, etc.
, certain support from policy and economic levels has been given, which has increased the confidence of enterprises in R&D and production of children's medicines
.
However, the industry also pointed out that to mobilize the enthusiasm of enterprises for R&D and production, it is also necessary to ensure that the relevant drugs remain within a reasonable profit range in order to improve the level of clinical children's drug use
.
For example, it is possible to explore a suitable procurement method specifically for the field of children's medicine, giving enterprises more enthusiasm for production
.
In general, the road to research and development of medicines for children is long, and the joint efforts of all links and relevant departments will be required in the future
.
